- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CORNERSTONE THERAPEUTICS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 121,14 | +1,70 % | Wenn die großen Pharmakonzerne Milliarden in Krebs investieren - entsteht der nächste Zelltherapie-Boom ganz woanders? | ||
| ZOETIS | 66,88 | -0,51 % | Zoetis Inc.: Zoetis Launches Lenivia (izenivetmab injection) in Canada and the European Union | Up to 40% of dogs may have radiographic osteoarthritis New long-acting monoclonal antibody therapy offers three months of osteoarthritis pain relief for dogs with a single injection Zoetis Inc.... ► Artikel lesen | |
| INCYTE | 102,90 | +0,88 % | Daten von Incyte werden im Rahmen von vier kurzen mündlichen Vorträgen auf dem European Society for Medical Oncology (ESMO)-Kongress 2026 vorgestellt und unterstützen die Bemühungen zur Verbesserung der Behandlungsergebnisse bei schwer ... | In kurzen mündlichen Vorträgen werden neue Phase-1-Daten aus dem gesamten Incyte-Portfolio für solide Tumoren vorgestellt Sowohl INCB161734, ein in der Erprobung befindlicher, hochwirksamer... ► Artikel lesen | |
| AMARIN | 12,500 | +0,81 % | Amarin Corporation plc: Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape | DUBLIN, Ireland and BRIDGEWATER, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide, applauds... ► Artikel lesen | |
| FILANA THERAPEUTICS | 0,923 | -2,74 % | Filana Therapeutics, Inc.: Filana Therapeutics Reports Q1 2026 Financial Results and Business Update | AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 260,00 | +0,78 % | Benchmark erhöht Kursziel für Ligand Pharma nach XOMA-Deal auf 335 $ | ||
| ACHIEVE LIFE SCIENCES | 5,300 | +0,95 % | Canaccord reiterates Achieve Life Sciences stock rating on CRL review | ||
| MADRIGAL PHARMACEUTICALS | 480,00 | +0,80 % | Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio | Received two new U.S. Rezdiffra- (resmetirom) patents in F2/F3; both patents will be listed in the FDA's Orange Book Received new U.S. resmetirom patent directed to a method of administering resmetirom... ► Artikel lesen | |
| ANI PHARMACEUTICALS | 72,00 | 0,00 % | ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter | Trial court denied Company's motion for a new trial and judgment as a matter of law for unjust enrichmentANI intends to appeal rulings to the Delaware Supreme Court and continue to seek to recover... ► Artikel lesen | |
| TALPHERA | 1,150 | -3,36 % | Talphera, Inc.: Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update | NEPHRO CRRT clinical study expected to be completed this year
Cash and investments of $21.1 million at March 31, 2026
Conference call and webcast to be held on Wednesday... ► Artikel lesen | |
| RIGEL PHARMACEUTICALS | 35,340 | +1,32 % | Rigel Pharmaceuticals, Inc.: Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer | Dr. Hannah has decades of oncology drug development experience and has served on Rigel's Board of Directors since 2021
She has resigned from Rigel's Board of... ► Artikel lesen | |
| SAVARA | 4,769 | -3,64 % | Savara Inc.: Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) | -- MHRA's Acceptance Follows Acceptance/Validation of MOLBREEVI Biologics License Application (BLA) and MAA in Autoimmune PAP by the U.S. Food and Drug Administration (FDA) and the European Medicines... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 2,100 | -1,41 % | Biodexa Pharmaceuticals Plc - F-1, Registration statement for certain foreign private issuers | ||
| ARTIVION | 22,400 | -0,88 % | Artivion, Inc.: Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis | ATLANTA, June 29, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that... ► Artikel lesen | |
| HERON THERAPEUTICS | 0,430 | +2,77 % | Heron Therapeutics, Inc.: U.S. District Court Issues Decision Regarding CINVANTI Patents | CARY, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. District Court... ► Artikel lesen |
Das Unternehmen CORNERSTONE THERAPEUTICS INC kann der Branche Pharma zugeordnet werden.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CORNERSTONE THERAPEUTICS INC finden Sie auf Wallstreet Online.